發送短信 : Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

  _____    __   __   _    _     ______    ______  
 / ____||  \ \\/ // | \  / ||  /_   _//  /_____// 
/ //---`'   \ ` //  |  \/  ||   -| ||-   `____ `  
\ \\___      | ||   | .  . ||   _| ||_   /___//   
 \_____||    |_||   |_|\/|_||  /_____//  `__ `    
  `----`     `-`'   `-`  `-`   `-----`   /_//     
                                         `-`